Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00516243 · ClinicalTrials.gov registry record · Phase 1
Defined Green Tea Catechin Extract in Treating Women With Hormone Receptor Negative Stage I-III Breast Cancer
A Phase 1 study of Stage II Breast Cancer and Stage IIIA Breast Cancer, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 4
- Study locations
NCT00516243 is a Phase 1 study of Stage II Breast Cancer and Stage IIIA Breast Cancer that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 40 participants, below the 318-participant average among 30 other Stage II Breast Cancer trials with a reported enrollment target (87% lower). The trial reports 4 study locations across 2 states.
The verdict
NCT00516243, a Phase 1 study of Stage II Breast Cancer and Stage IIIA Breast Cancer, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 4
- Study locations
Study Summary
This randomized phase I trial studies the side effects and best dose of defined green tea catechin extract in treating women with hormone receptor-negative stage I-III breast cancer. Green tea extract contains ingredients that may prevent or slow the growth of breast cancer.
Conditions Studied
Interventions
- OTHER placebo
- OTHER quality-of-life assessment
- PROCEDURE laboratory biomarker analysis
- PROCEDURE questionnaire administration
- DRUG defined green tea catechin extract
Study Locations (4)
New York
- Columbia University Medical Center - New York
- Memorial Sloan-Kettering Cancer Center - New York
Texas
- Baylor College of Medicine - Houston
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2007-07 |
| Est. Completion | 2010-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00516243
The ClinicalTrials.gov registry entry for NCT00516243 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 318-participant average among 30 other Stage II Breast Cancer trials with a reported enrollment target (87% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Stage II Breast Cancer appearing as the primary indexed condition, and to 5 interventions - of which placebo is the first listed.
NCT00516243 reports 4 study locations spanning 2 distinct geographic areas - top geographies include New York, Texas.
Frequently Asked Questions
What is clinical trial NCT00516243 about?
NCT00516243 is a clinical study titled "Defined Green Tea Catechin Extract in Treating Women With Hormone Receptor Negative Stage I-III Breast Cancer". This randomized phase I trial studies the side effects and best dose of defined green tea catechin extract in treating women with hormone receptor-negative stage I-III breast cancer. Green tea extract contains ingredients that may prevent or slow the growth of breast cancer.
What is the current status of trial NCT00516243?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2007-07. Estimated completion is 2010-03.
What conditions does trial NCT00516243 study?
This clinical trial studies the following conditions: Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage I Breast Cancer, Estrogen Receptor-negative Breast Cancer.
What interventions are being tested in trial NCT00516243?
The interventions under investigation include: placebo (OTHER), quality-of-life assessment (OTHER), laboratory biomarker analysis (PROCEDURE), questionnaire administration (PROCEDURE), defined green tea catechin extract (DRUG).
Who is sponsoring clinical trial NCT00516243?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00516243 being conducted?
This trial has 4 study locations across New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage II Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer
COMPLETED · Phase 1
-
A Study of Disappearing Markers for Daily Radiation Treatment Delivery for Breast Cancer Patients.
RECRUITING · NA
-
TeleHealth Resistance Exercise Intervention to Preserve Dose Intensity and Vitality in Elder Breast Cancer Patients
RECRUITING · NA
-
Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer
RECRUITING · Phase 2
-
Improving Exercise Capacity With a Tailored Physical Activity Intervention
RECRUITING · NA
-
A Study of Revaree Plus in People With Breast Cancer
RECRUITING · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.